Senior Developer, Clinical Biochemistry and Immunology; Assistant Professor of Laboratory Medicine and Pathology, Mayo Clinic
BIOGRAPHY
Speakers
-
Roger Klein, MD, JD
Principal, Consulting Faculty Fellow, Center for Law, Science, and Innovation Arizona State University Law SchoolBIOGRAPHY -
Sam Caughron, MD
President and CEO, MAWD Pathology GroupBIOGRAPHY
Abstract
Presentation Goals:
- To provide a discussion space where three experts discuss the FDA LDT ruling and its implications for their lab practices and patient impact practices
- Allow for an audience-driven discussion with the assistance of a moderator. Attendees can submit Qs in which the moderator prompts and the panel addresses.
- Will take the format of a fireside chat
Learning Objectives:
-
Discuss the FDA LDT ruling and it's implication for lab practices and patient impact practices
-
Clarify outstanding uncertainty regarding the FDA LDT ruling through the aid of a moderator
-
Apply input from experts to their specific lab situation
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
FEB 25, 2025 | 1:00 PM
Quality efforts in the clinical laboratory are always under the microscope- a hyper-focus for laboratorians from start to finish. Recognizing the external factors that affect hemostasis test...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...